Abstract
BackgroundThe accurate information about burden of multiple myeloma (MM) at national and provincial level remains unknown in China.MethodsFollowing the general analytical strategy used in GBD 2016, the age-, sex-, and province-specific incidence and mortality in China were analyzed. Trends in the incidence and mortality from 2006 to 2016 were evaluated.ResultsIt was estimated that there were 16,500 new cases and 10,300 deaths of multiple myeloma in China in 2016. The age-standardized incidence rates (ASIR) and mortality rates (ASMR) per 100,000 population were 1.03 (95% UI, 0.88–1.17) and 0.67 (95% UI, 0.59–0.77) in 2016. Males had higher incidence and mortality rates than females in all age groups. An upward trend with age in incidence and mortality was observed. Higher incidence and mortality rates clustered in the developed provinces. The incidence of MM in China increased significantly from 2006 to 2016, while the mortality increased from 2006 to 2014, and remained stable from 2014 to 2016.ConclusionThe burden of MM showed a heterogeneous pattern in China, which highlighted the need of tailored disease prevention and control strategies in both national and provincial levels.
Highlights
The accurate information about burden of multiple myeloma (MM) at national and provincial level remains unknown in China
Data sources Details of the methodology used in the Global Burden of Disease 2016 (GBD 2016) study have been explained in previous studies [5,6,7]
After the age of 15 years, the incidence and mortality rates increased steadily with age, and higher incidence and mortality rates of multiple myeloma were seen in the individuals over 60 years (Table 1, Fig. 1)
Summary
The accurate information about burden of multiple myeloma (MM) at national and provincial level remains unknown in China. In 2016, the incident cases of MM in the most populous countries were 139,000 with the rank of 26 among all cancers, and death number was 98,000 with the rank of 22 among all cancers [2]. According to the statistics of GLOBOCAN 2018, MM accounted for 0.9% of all new cancer cases and 1.1% of all cancer deaths worldwide in 2018 [3]. Accurate epidemiologic study of MM based on national and province level has not been conducted in China. In this analysis, we sought to determine the incidence and mortality of multiple myeloma in China in 2016 and analyze temporal trends from 2006 to 2016
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
